← Browse by Condition

Medical Condition

ulcerative colitis

Total Trials

20

Recruiting Now

20

Trial Phases

Phase 3, Phase 4, Phase 2

ClinicalMetric tracks all active clinical trials for ulcerative colitis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — ulcerative colitis Clinical Trials

How many clinical trials are currently recruiting for ulcerative colitis?

ClinicalMetric currently tracks 20 actively recruiting clinical trials for ulcerative colitis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 20. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for ulcerative colitis?

ulcerative colitis research spans Phase 2 (5 trials), Phase 3 (3 trials), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a ulcerative colitis clinical trial?

Eligibility criteria for ulcerative colitis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

5

Phase 3

3

Phase 4

2

Top Sponsors

AbbVie 3 trials

Assistance Publique - Hôpitaux de Paris 2 trials

University of Texas at Austin 1 trial

Second Affiliated Hospital, School of Medicine, Zhejiang University 1 trial

Barts & The London NHS Trust 1 trial

Recruiting Clinical Trials

Registry and Biorepository for IBD in Central Texas

University of Texas at Austin

NCT07071519 Phase 3

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

United States, Belgi...

NCT06609447 Phase 4

The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis

Second Affiliated Hospital, Sc...

Nutrition and Clinical Outcomes in IBD

Barts & The London NHS Trust

NCT07223424 Phase 2

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT03804931 Phase 2, Phase 3

Fecal Microbiota Transplantation for Ulcerative Colitis

Guangzhou First People's Hospi...

Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis

Assistance Publique - Hôpitaux...

Digestive Biobank for Exploring Microbiota-host Interactions

Assistance Publique - Hôpitaux...

NCT07064707 Phase 2

Rupatadine in Patients With Ulcerative Colitis

Alexandria University

Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT06405087 Phase 3

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

United States, Belgi...

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

NCT06029972 Phase 2

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

United States, Austr...

Gilead Sciences

Mirikizumab Real World Protocol

United States, Canad...

University of North Carolina, ...

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study

University Hospitals Coventry ...

NCT04743518 Phase 4

Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis

Centre Hospitalier Universitai...

GWA Study in Patients With Inflammatory Bowel Disease

Chinese University of Hong Kon...

Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease

McMaster University

NCT06421818 Phase 2

Effect and Mechanism of Baitouweng Decoction for Large Intestine Damp-heat Syndrome of Ulcerative Colitis

The Second Hospital of Nanjing...

Related Conditions

inflammatory bowel diseases (5) crohn disease (4) crohn s disease (4) malnutrition (1) sarcopenia (1) renal cell carcinoma (1) non small cell lung cancer (1) melanoma (1) colo rectal cancer dmmr msi h crc (1) hepatocellular carcinoma (1) esophageal cancer (1) squamous cell carcinoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology